Biotest Aktiengesellschaft (ETR:BIO) Stock Price Up 1%

Biotest Aktiengesellschaft (ETR:BIOGet Free Report) was up 1% during mid-day trading on Monday . The stock traded as high as €42.40 ($46.09) and last traded at €42.40 ($46.09). Approximately 860 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 1,927 shares. The stock had previously closed at €42.00 ($45.65).

Biotest Aktiengesellschaft Stock Down 0.5 %

The company has a market capitalization of $835.14 million, a PE ratio of 18.43 and a beta of 0.27. The company has a debt-to-equity ratio of 151.29, a quick ratio of 1.66 and a current ratio of 5.00. The stock’s 50 day moving average is €42.33 and its 200 day moving average is €42.48.

Biotest Aktiengesellschaft Company Profile

(Get Free Report)

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis.

Featured Stories

Receive News & Ratings for Biotest Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotest Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.